Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Hotline I: ADVANCE - Action in Diabetes and Vascular Disease. 708003
Vienna, Austria, 2 September 2007: The largest-ever study of treatments for diabetes has shown that a fixed combination of two blood pressure lowering drugs reduces the risk of death, as well as the risks of heart and kidney disease. Results from the ADVANCE (Action in Diabetes and Vascular Disease) Study were presented today at the European Society of Cardiology Congress 2007 in Vienna. One of the study leaders, Professor Stephen MacMahon from The George Institute for International Health in Australia, said "these results represent an important step forward in health care for the millions of people with diabetes worldwide. This treatment reduced the likelihood of dying from the complications of diabetes by almost one-fifth, with virtually no side-effects.” Globally, there are approximately 250 million people with diabetes, most of whom will eventually be killed or disabled by the complications of their condition. The most common cause of death in people with diabetes is heart disease. Kidney disease also affects a large proportion. In 2006, the United Nations issued a statement calling for increased international action to combat the global epidemic of diabetes. A total of 11 140 patients with diabetes from 20 countries world wide participated in the 4.3 year project. Half received daily treatment with a single tablet containing fixed combination of two blood pressure lowering drugs (perindopril and indapamide) and half received matching inactive placebo. Dr. Anushka Patel, Study Director also from The George Institute, said “the participants in ADVANCE were already receiving most of the usual treatments provided to patients with diabetes, including other drugs to lower blood pressure. However, addition of the fixed combination of perindopril and indapamide reduced the risk of death from any cause by 14% and the risk of death from cardiovascular disease by 18%. In absolute terms, one death would be avoided for every 79 patients treated with the fixed combination of perindopril and indapamide for 5 years. The risk of coronary heart disease events was reduced by 14% and the risk of new or worsening kidney disease was reduced by 21%.
Professor John Chalmers, the author of previous international guidelines for the treatment of high blood pressure and chairman of the study management group, said, “the results clearly demonstrate that we have the tools to blunt the impact of the global diabetes epidemic facing rich and poor countries alike. But concerted action is urgently required to ensure that patients with diabetes are identified and provided with treatments proven to improve important outcomes like survival.”
This study was presented at the ESC Congress 2007 in Vienna.
The ADVANCE Study was conducted by an international group of independent medical researchers with support from Servier, the manufacturer of perindopril and indapamide, and the National Health and Medical Research Council of Australia. Perindopril is an angiotensin converting enzyme (ACE) inhibitor and indapamide is a thiazide-like diuretic. The fixed combination of perindopril and indapamide is marketed in 97 countries worldwide under the brand names Preterax™ ,Predonium™, Biprel, Prelectal, Noriplex or Noliprel The study was coordinated by The George Institute at the University of Sydney. The George Institute is a renowned international medical research centre with branches in Sydney, Beijing, Hyderabad and London.
© 2017 European Society of Cardiology. All rights reserved